Cory berkland

Introduction. With approximately 174,000 cases per year, luminal breast cancers are the most common forms of breast cancer diagnosed in the US and Canada [1, 2].In contrast to Her2-overexpressing breast cancers, or triple negative breast cancers, which lack expression of estrogen receptor (ER), Progesterone receptor, and Her2, luminal breast cancers frequently express hormone and Her2 ...

Purpose Encapsulation of liquids into biodegradable polymer microcapsules has been a challenging task due to production limitations stemming from solution viscosity, phase stabilization, molecular localization, and scalable production. We report an extension of Precision Particle Fabrication (PPF) technology for the production of monodisperse …Cory Berkland. Solon E. Summerfield Distinguished Professor ; PHARMACEUTICAL CHEMISTRY; Contact Info. 785-864-1455. Multidisciplinary Research Building, Room 320D 2030 Becker Drive Lawrence, KS 66047 Learned Hall, Room 4160C 1530 West 15th Street Lawrence, KS 66045 Personal Links.He received MS and PhD degrees from the Department of Chemical and Biomolecular Engineering at the University of Illinois in Urbana-Champaign and a BS degree in Chemical Engineering from Iowa State University in Ames. Prof. Berkland is a co-founder of Orbis Biosciences, Savara Pharmaceuticals, Bond Biosciences and Orion BioScience.El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res. 2009; 26:1752-1763. [PMC free article] [Google Scholar] El-Gendy N, et al. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci. 2009; 98:2731-2746.Modeling release of small molecules from degradable microspheres is important to the design of controlled-release drug delivery systems. Release of small molecules from poly(d,l-lactide-co-glycolide) (PLG) particles is often controlled by diffusion of the drug through the polymer and by polymer degradation.Orion BioScience was founded by Dr. Joshua Sestak and Prof. Cory Berkland and the company is based out of Omaha, Nebraska.----

The company's lead candidate, BBI-001, is an iron chelator for the treatment of hereditary hemochromatosis. Bond joins the St. Louis ecosystem after licensing technology originally developed at the University of Kansas. Bond was founded by St. Louisan and serial entrepreneur Cory Berkland, PhD.BERKLAND LAB TEAM. Our group is made up of extraordinary people that are well versed in the synthesis and characterization of polymers and colloids, validating and quantifying conjugation reactions, and formulating these materials for in vivo applications. They have developed novel approaches for controlling the physicochemical properties of ...Author: Susan MacNally Created Date: 08/20/2021 11:09:00 Title: Conflict management plan for Cory Berkland (L0013204-5).DOC Subject: L0013204 / 5 Last modified by1. Introduction. Injectable scaffolds have received attention due to their potential for avoiding the invasive surgery typically required for tissue implantation. 1 From a clinical perspective, the use of injectable materials is an attractive alternative to surgery as it reduces the risk of infection, scar formation, patient discomfort and the cost of treatment. 2 Injectable scaffolds may be ...C. Berkland et al. Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions. J. Controlled Release (2001) ... Cory Berkland. Functions of the plasminogen receptor Plg‐R KT. Journal of Thrombosis and Haemostasis, Volume 18, Issue 10, 2020, pp. 2468-2481.Dr. Hartwell obtained her Ph.D. in biomolecular engineering with Cory Berkland at the University of Kansas as a Madison and Lila Self Graduate Fellow. Her doctoral research focused on developing an antigen-specific immunotherapy to treat multiple sclerosis while determining cellular and molecular mechanisms of tolerance.GI/ORAL. Citation: Dormer N, Berkland C, "Single-Step Functional Coatings for Increased Efficiencies". ONdrugDelivery Magazine, Issue 77 (Jul 2017), pp 28-31. In this article about oral drug innovation, Cory Berkland and Nathan Dormer focus on how enterics and reverse enterics are applied into dosage forms, and discuss the future of this ...

Singkome Tima, 1 Siriporn Okonogi, 2 Chadarat Ampasavate, 2 Chad Pickens, 3 Cory Berkland, 3, * and Songyot Anuchapreeda 4, * Singkome Tima 1 Nanoscience and Nanotechnology Program, Graduate School, Chiang Mai University, Chiang Mai 50200, ThailandThree decades of promise have culminated in the development of gene therapies that can be applied to a broad range of human diseases. After a brief history, we provide an overview of gene therapy types and delivery methods, gene editing technologies, regulatory affairs, clinical trials, approved pro … Cory Berkland, Solon E. Summerfield Distinguished Professor in the departments of Pharmaceutical Chemistry and Chemical & Petroleum Engineering, is the fourth KU professor to earn the honor. ... Berkland joined KU in 2004, and his research blends engineering and biological sciences. As biotechnology improves methods for processes like tissue ...Berkland . If}!1. 4~:J . Dr. Mark Cohen . Date Defended: April 26, 20 II . ... Cory Berkland, and Mark Cohen for taking time out of their busy schedules to read my dissertation and for offering valuable suggestions. Also, I give many thanks to all present and past Forrest lab members: Adel Alhowyan,Cory Berkland Date Defended: 11 July 2019. ii The thesis committee for Hao Lou certifies that this is the approved version of the following thesis: The Application of Machine Learning Algorithms in Understanding the Effect of Core/Shell Technique on Improving Powder Compactability

Msf nakia iso 8.

AU - Berkland, Cory J. N1 - Funding Information: The authors are thankful to the University of Kansas, KS, USA, Washington University, St. Louis, MO, USA, the Deanship of Scientific Research (DSR) at King Abdulaziz University, and the Mohamed Saeed Tamer Chair for Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia for ...Fang WB, Yao M, Jokar I, Alhakamy N, Berkland C, Chen J, Brantley-Sieders D, Cheng N. The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells. Breast Cancer Res Treat.Berkland serves as the Chairman of the Board, President, Chief Executive Officer (CEO), and Co-Founder of Bond Biosciences. He is taking a part ial leave as Distinguished Professor at The University of Kansas to advance the business and to ensure the development and clinical trial progression of BBI-001.El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res. 2009; 26:1752-1763. [PMC free article] [Google Scholar] El-Gendy N, et al. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci. 2009; 98:2731-2746.Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice Jun Yang1,2, Sheng-Xue Xie3, Yiling Huang1,4, Min Ling1, Jihong Liu2, Yali Ran1, Yanlin Wang4, J Brantley Thrasher1, Cory Berkland3, and Benyi Li*,1,4 1Department of Urology, The University of Kansas Medical Center, Kansas City, KS 66160, USA

The potential of this polymer for siRNA delivery was assessed. This triblock copolymer formed nanocapsules with high siRNA encapsulation efficiency that protected siRNA from degradation in serum. Capsules were pH-sensitive and deformed when pH decreased below 6. In vitro RNAi evaluation demonstrated that the capsules are capable of delivering ...Bradley J. Newell. Interim Assistant Dean - Wichita. Director - PGY-1 Community-Based Pharmacy Residency (DIllons) Clinical Assistant Professor. School of Pharmacy - Administration. Department of Pharmacy Practice. Dept. of Family & Community Med., KU Med., Wichita. View full profile.Cory Berkland, PhD President, CEO and Chairman. Dr. Berkland serves as the Chairman of the Board, President, Chief Executive Officer (CEO), and Co-Founder of Bond Biosciences.Qingting Hu, 1 Megan Myers, 1 Wei Fang, 1 Min Yao, 1 Gage Brummer, 1 Justin Hawj, 1 Curtis Smart, 1 Cory Berkland, 2 and Nikki Cheng 1, 3, * Qingting Hu 1 Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USACory Berkland. Connect About Experience Recommendations. Saint Louis, Missouri, United States. Interested in Entrepreneur Technologically Savvy. Orbis Biosciences - Aquired by Adare Pharmaceuticals in 2020 Savara Pharmaceuticals - NASDAQ listed in 2017. Experience.ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. HHS Author Manuscripts. Nanoparticles of PLG have been widely studied for their use in drug delivery. 8600 Rockville Pike Bethesda, MD 20894. HHS Vulnerability Disclosure.C. Berkland et al. Precise control of PLG microsphere size provides enhanced control of drug release rate. J. Control. Release (2002) ... Cory Berkland. Protein Encapsulation in and Release from Monodisperse Double-Wall Polymer Microspheres. Journal of Pharmaceutical Sciences, Volume 102, Issue 5, 2013, pp. 1601-1609 ...Nashwa El-Gendy, Mark M. Bailey, Cory Berkland; Pages 283-312. Liposomes for Pulmonary Drug Delivery. Janani Swaminathan, Carsten Ehrhardt; Pages 313-334. Nanoparticles for Pulmonary Delivery. Alan B. Watts, Robert O. Williams III; Pages 335-366. Pulmonary Delivery of Plasmid DNA for Disease Prevention and Therapy.Berkland, Cory J. Publisher. Nature Publishing Group. Type. Article. Article Version. Scholarly/refereed, publisher version. Metadata Show full item record. Abstract. Autoimmune diseases such as multiple sclerosis (MS) are typified by the misrecognition of self-antigen and the clonal expansion of autoreactive T cells. Antigen-specific ...

Cory Berkland; Content type: Research Article Published: 06 September 2014; Pages: 1185 - 1193; This is part of 1 collection: Theme: Nanoparticles in Vaccine Delivery; A Therapeutic Microparticle-Based Tumor Lysate Vaccine Reduces Spontaneous Metastases in Murine Breast Cancer Authors (first, second and last of 5) ...

Chad Groer 1 , Ti Zhang 1 , Ruolin Lu 2 , Shuang Cai 1 , Derek Mull 1 2 , Aric Huang 2 , Melanie Forrest 1 , Cory Berkland 2 3 , Daniel Aires 1 4 , Marcus Laird Forrest 1 2 Affiliations 1 HylaPharm LLC, 2029 Becker Dr, Lawrence, Kansas 66047, United States.If delivered as a suspension, such small particles are also prone to particle growth due to Ostwald ripening and can suffer from uncontrolled agglomeration (Berkland, 2010). A major obstacle to inhaled therapeutics is the inability to efficiently deliver large quantities of a drug to the deep lung (Gillian, 2010).Nashwa El-Gendy1, Kristin L. Aillon1, and Cory Berkland1,2,* 1Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66047 ... Fax: (785) 864- 1454. [email protected]. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our1. Introduction to hyaluronic acid. Hyaluronic acid (HA), also named hyaluronan, is a high molecular weight (10 5 –10 7 Da) naturally occurring biodegradable polymer. HA is an unbranched non-sulfated glycosaminoglycan (GAG) composed of repeating disaccharides (β-1,4-D-glucuronic acid (known as uronic acid) and β-1,3-N-acetyl-D-glucosamide) (Figure 1) [1–3].Hyaluronic acid (HA) is a naturally occurring biodegradable polymer with a variety of applications in medicine, including scaffolding for tissue engineering, dermatological fillers and viscosupplementation for osteoarthritis treatment. HA is available in most connective tissues in body fluids such as synovial fluid and the vitreous humor of …Abdulgader A. Baoum1 and Cory J. Berkland1,2,* 1Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS ... Baoum and Berkland Page 3 J Pharm Sci. Author manuscript; available in PMC 2014 October 23. NIH-PA Author Manuscript. gene delivery in vivo28,39-41. One approach for overcoming this limitation was to link theName: CORY BERKLAND Phone: (785) 864-1455 Email: [email protected]. Business Contact. Name: CORY BERKLAND Phone: (785) 764-0125 Email: [email protected]. Research Institution. N/A . Abstract. PROJECT SUMMARY/ABSTRACT Hereditary Hemochromatosis (HH) is one of the most common genetic disorders in the United …Cory Berkland, CEO [email protected]. Release Summary. Phase Ia/b will assess the safety of BBI-001 and test the ability of BBI-001 to prevent iron uptake from food. Contacts.

Apartments for 1100 a month.

Kansas v kansas state score.

Abstract: Particles for delivery of active ingredients formed from an active ingredient and a hydrophobic matrix, as well as methods for making such particles. Type: Grant. Filed: August 16, 2019. Date of Patent: February 14, 2023. Assignee: ADARE PHARMACEUTICALS USA, INC. Inventors: Cory Berkland, Milind Singh.Nashwa El-Gendy, Mark M. Bailey, Cory Berkland; Pages 283-312. Liposomes for Pulmonary Drug Delivery. Janani Swaminathan, Carsten Ehrhardt; Pages 313-334. Nanoparticles for Pulmonary Delivery. Alan B. Watts, Robert O. Williams III; Pages 335-366. Pulmonary Delivery of Plasmid DNA for Disease Prevention and Therapy.Number of Employee Profiles 2. Bond Biosciences has 2 current employee profiles, including Co-founder and Chief Scientific Officer Cory Berkland. Cory Berkland Co-founder and Chief Scientific Officer.Cory Berkland. The Berkland Lab investigates pharmaceuticals and biomaterials. They aim to understand the transport of pharmaceuticals as a function of physical and chemical properties. Biomaterials are also investigated for applications in regenerative medicine. Faculty Profile. Berkland Research Lab.Cory Berkland. Professor Cory Berkland's lab continues to bridge research in Pharmaceutical Chemistry, Chemical Engineering, and Bioengineering at KU. The lab recently completed a research collaboration with Orion BioScience sponsored by the Juvenile Diabetes Research Foundation aiming to prevent the progression of Type 1 Diabetes using ...Cory Berkland PhD, University of Illinois, 2003 MS, University of Illinois, 2001 BS, Iowa State University, 1998 View All People contact info: Email: [email protected] The Berkland lab focuses on developing new therapeutics and biomaterials for improving human health Emily C. Beck, Brooke L. Lohman, Daniel B. Tabakh, Sarah L. Kieweg, Stevin H. Gehrke, Cory J. Berkland, Michael S. Detamore. Enabling Surgical Placement of Hydrogels Through Achieving Paste-Like Rheological Behavior in Hydrogel Precursor Solutions. Annals of Biomedical Engineering 2015, 43 (10) , 2569-2576.Singkome Tima, 1 Siriporn Okonogi, 2 Chadarat Ampasavate, 2 Chad Pickens, 3 Cory Berkland, 3, * and Songyot Anuchapreeda 4, * Singkome Tima 1 Nanoscience and Nanotechnology Program, Graduate School, Chiang Mai University, Chiang Mai 50200, ThailandJ. Daniel Griffin, Martin A. Leon, Jean R. Salash, Michael Shao, Brittany L. Hartwell, Chad J. Pickens, Joshua O. Sestak, Cory Berkland. Acute B-Cell Inhibition by Soluble Antigen Arrays Is Valency-Dependent and Predicts Immunomodulation in Splenocytes. Biomacromolecules 2019, 20 (5) , 2115-2122.Wei Bin Fang 1, Min Yao , Gage Brummer , Diana Acevedo , Nabil Alhakamy2, Cory Berkland 2 , Nikki Cheng 1 1 Department of Pathology and Laboratory, University of Kansas Medical Center, Kansas City, KS 66160, USAAbstract. Lung surfactant is crucial for optimal pulmonary function throughout life. An absence or deficiency of surfactant can affect the surfactant pool leading to respiratory distress. Even if the coupling between surfactant dysfunction and the underlying disease is not always well understood, using exogenous surfactants as replacement is ... ….

Noncovalently associated cell-penetrating peptides for gene delivery applications. 2013 Jun;4 (6):741-57. doi: 10.4155/tde.13.44. Nabil A Alhakamy Adane S Nigatu Cory J Berkland Joshua D Ramsey. Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA. 23738670.TY - JOUR. T1 - Monodisperse liquid-filled biodegradable microcapsules. AU - Berkland, Cory. AU - Pollauf, Emily. AU - Varde, Neel. AU - Pack, Daniel W.Cory Berkland, PhD: Cory Berkland holds the Solon E. Summerfield Distinguished Professorship in the Department of Pharmaceutical Chemistry and in the Department of Chemical Engineering at The University of Kansas.A critical step in the development of autoimmune diseases is the stimulation of immune cells against endogenous antigen. Here, we investigate soluble antigen arrays (SAgAs) capable of suppressing autoimmune response to antigen.Cory Berkland. Cory Berkland. Solon E. Summerfield Distinguished Professor. Department of Pharmaceutical Chemistry. Contact Info. [email protected] mobility on the cell surface leads to a phenomenon called “clustering” during ligand binding 34. The size of ICAM-1 and the steric hindrance effect are two significant factors in receptor clustering during ligand binding to ICAM-1, dictating that the receptors stay at an optimum distance from each other 35 – 36.Nov 11, 2011 · If delivered as a suspension, such small particles are also prone to particle growth due to Ostwald ripening and can suffer from uncontrolled agglomeration (Berkland, 2010). A major obstacle to inhaled therapeutics is the inability to efficiently deliver large quantities of a drug to the deep lung (Gillian, 2010). Europe PMC is an archive of life sciences journal literature.1. INTRODUCTION. Hyaluronic acid (HA) is a linear biopolymer component of multiple approved products and exhibits versatility for drug delivery, since it is available in a wide range of molecular weights and offers multiple sites for chemical modification. 1-6 In the human body, HA is prevalent in cartilage, skin, and synovial fluid and is typically present as a very high molecular weight ... Cory berkland, [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1]